Acadia Pharmaceuticals | ACAD - Ordinary Share Capital


Acadia Pharmaceuticals reported $169.18M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
ALKERMES USD 165.61M 503K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Cara Therapeutics USD 9.38M 9.38M Sep/2025
Corcept Therapeutics USD 105.97M 842K Dec/2025
Cytokinetics USD 122.26M 145K Dec/2025
Eisai JPY 282.11M 1000 Dec/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Incyte USD 198.46M 2.33M Dec/2025
J&J USD 2.41B 584K Sep/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Pfizer USD 5.69B 1000K Sep/2025
Prothena USD 53.83M 3K Dec/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Sarepta Therapeutics USD 104.96M 196K Dec/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vanda Pharmaceuticals USD 58K 0 Dec/2024
Vertex Pharmaceuticals USD 254M 0 Dec/2025